The New England Journal of Medicine

 

BEditorial

 

Volume 346:1663-1665

May 23, 2002

Number 21

 

Physician-Assisted Death — A Last Resort?

 

During the past decade, patients with the uncommon disease amyotrophic lateral sclerosis (ALS) have had a prominent role in the debate about physician-assisted suicide and voluntary active euthanasia. In Canada and Great Britain, patients with ALS have challenged legal bans on physician-assisted death. A widely viewed videotape of a patient in the Netherlands choosing euthanasia generated considerable controversy. In the United States, millions watched Jack Kevorkian euthanize Thomas Youk, a patient with ALS, on the CBS news program 60 Minutes.

As compared with patients with other terminal illnesses, those with ALS are more likely to request physician-assisted death. Veldink et al.1 report in this issue of the Journal that in the Netherlands, patients with ALS are twice as likely as patients with cancer to die with the assistance of a physician. In Oregon, where assisted suicide for terminally ill patients was legalized by the Death with Dignity Act, 5 percent of all deaths among patients with ALS in 1999 were from assisted suicide, as compared with 0.4 percent of deaths in the state among patients with cancer.2 Even before the final enactment of this legislation, 44 of 100 surveyed patients with ALS in Oregon and Washington indicated that they planned to request a lethal prescription.3 One third of these patients explicitly discussed their desire for a lethal prescription during the month before they died, and all but one had expressed an interest in assisted suicide when interviewed an average of 11 months earlier.4 In contrast, between 9 and 27 percent of surveyed patients with cancer in the United States and Canada express a serious interest in hastened death, assisted suicide, or euthanasia.5,6,7,8,9

Studies of patients in Oregon who made explicit requests for assisted death or who died by assisted suicide suggest that the loss of autonomy, control, independence, and the ability to pursue pleasurable activities — all hallmarks of ALS — often underlie requests for hastened death.2,10 Lavery et al., in a qualitative study involving patients with human immunodeficiency virus infection, describe the desire for assisted suicide as stemming from two factors: fear of worsening symptoms and loss of function, and progressive loss of the ability to maintain close personal relationships.11 In advanced ALS, immobility and difficulties with communication lead to isolation and separation from others.

Depression can contribute to the desire to die. In surveys of patients with cancer, depression is consistently associated with interest in hastened death, assisted suicide, and euthanasia.5,6,7,8,9 However, we found no relation between depression and interest in assisted suicide among patients with ALS.3 A stronger and more specific psychological mediator of the desire to die may be hopelessness, which can occur in the absence of depression.9 Dysphoria and inability to experience pleasure in the present are cardinal features of depression. Hopelessness projects these feelings into the future. In patients with ALS, hopelessness, measured earlier in the course of the disease, but not depression, strongly predicted an interest in assisted suicide in the final month of life.4 The invariability of the progression of disease in ALS robs many patients of the hope that the most dreaded symptoms can be avoided. The belief that tomorrow is likely to be worse than today may be an important factor in these decisions.

Is it possible that patients with ALS have less access than other terminally ill patients to palliation of suffering? Experts assert that with excellent palliative care, most requests for hastened death would not be made. We know little about the quality and availability of palliative care in the Netherlands that would provide a context for the findings of Veldink et al. Data reported voluntarily by ALS treatment centers throughout the United States suggest that many therapeutic strategies that might improve the quality of life for patients with ALS — including treatments for depression, sialorrhea, hypoventilation, and dysphagia — are underused.12 In this country, almost half of the patients with ALS who die at home are enrolled in hospice programs. Whether they receive excellent palliative care remains unclear. For example, terminally ill patients greatly value not being a burden to their families.13 Yet, even among patients with ALS who are receiving home care services, family members deliver an average of 11 hours of direct care per day.14

What is needed in order to understand and address the preference of patients with ALS for hastened death? First, the psychological defenses of health care practitioners may result in a particular deafness to patients' reports of the actual experience of living with progressive ALS. In focusing on efforts to modify the progression of the disease, clinicians may fail to attend adequately to the symptoms, the existential issues, the family burden, and the hopelessness that patients face. This limited orientation is certainly evident in research on ALS, which is dominated by studies of pathogenesis, prevention, and cure.

Researchers must begin by listening to patients with ALS. Qualitative studies could help define what in the experience of patients leads to a desire for hastened death. We need prospective studies that can describe accurately the physical and psychological symptoms and existential viewpoints that predict the desire to die. As Veldink et al. report, 36 percent of patients with ALS in the Netherlands prepared advance directives for euthanasia, so it might be possible to identify those who might be interested in assisted suicide or euthanasia early enough in the course of their illness to intervene. Studies designed to test a variety of interventions among patients might answer critical questions as to the mutability of the preference for early death. The ALS research community, therefore, needs to advocate for more studies of the management of symptoms, quality of life, the experience of patients, and interventions aimed at reducing suffering. Such studies might bolster clinicians' confidence that they can help patients with ALS, so that they would not reinforce the hopelessness and fear these patients already feel.

Research efforts in ALS and other terminal diseases may reduce, but are unlikely to eliminate, the desire for hastened death among terminally ill patients. Our best palliative care, with meticulous attention to the whole person — including physical, spiritual, psychological, and relational aspects — may not change preferences that are based on values, life experiences, and ingrained coping mechanisms. Nonetheless, efforts to pursue intensive palliative treatments and to reduce suffering are warranted. Not only do such efforts decrease interest in euthanasia, but they affirm patients' humanity and have the potential to ameliorate the profound dread that many people suffer as they face the end of life.

Physician-assisted death may be an acceptable option of last resort for a very small number of terminally ill patients. At this point, we do not know what rates of physician-assisted death are appropriate. High rates would suggest that the procedure is not just being used as a humane approach to eliminating intractable suffering at the request of the patient. Rather, high rates could reflect deficiencies in the competence of health care practitioners, lack of access to suitable services, devaluation of the dying, or even pressures from others to end life prematurely. Judging from our clinical and research experience with patients with ALS and cancer, the rates of physician-assisted death that Veldink et al. report — 10 percent among patients with cancer and 20 percent among patients with ALS — are unacceptably high.

If society values the dying and can ensure respectful medical care for all terminally ill patients, then legalized physician-assisted death should be relevant in only a small number of cases. But this means that substantial resources and cultural change are necessary. We need the resources to improve the education of health care professionals, a commitment to ongoing societal dialogue about the care of the dying, and a guarantee of universal access to good care for all terminally ill persons, with monitoring of quality to ensure that such care is provided. The challenge for states and countries considering laws permitting physician-assisted death will be to tie legalization to such a pledge.


Linda Ganzini, M.D.
Department of Veterans Affairs Medical Center
Portland, OR 97201


Susan Block, M.D.
Dana–Farber Cancer Institute
Boston, MA 02115

The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.

References

  1. Veldink JH, Wokke JHJ, van der Wal G, de Jong JMBV, van den Berg LH. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 2002;346:1638-1644.[Abstract/Full Text]
  1. Sullivan AD, Hedberg K, Hopkins D. Legalized physician-assisted suicide in Oregon, 1998-2000. N Engl J Med 2001;344:605-607.[Full Text]
  1. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med 1998;339:967-973.[Abstract/Full Text]
  1. Ganzini L, Silveira MJ, Johnston WS. Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington. J Pain Symptom Manage (in press).
  1. Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA 2000;284:2460-2468.[ISI][Medline]
  1. Emanuel EJ, Fairclough DL, Daniels ER, Clarridge BR. Euthanasia and physician-assisted suicide: attitudes and experiences of oncology patients, oncologists, and the public. Lancet 1996;347:1805-1810.[ISI][Medline]
  1. Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. Am J Psychiatry 1995;152:1185-1191.[Abstract]
  1. Wilson KG, Scott JF, Graham ID, et al. Attitudes of terminally ill patients toward euthanasia and physician-assisted suicide. Arch Intern Med 2000;160:2454-2460.[ISI][Medline]
  1. Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000;284:2907-2911.[ISI][Medline]
  1. Ganzini L, Nelson HD, Schmidt TA, Kraemer DF, Delorit MA, Lee MA. Physicians' experiences with the Oregon Death with Dignity Act. N Engl J Med 2000;342:557-563. [Erratum, N Engl J Med 2000;342:1538.][Abstract/Full Text]
  1. Lavery JV, Boyle J, Dickens BM, Maclean H, Singer PA. Origins of the desire for euthanasia and assisted suicide in people with HIV-1 or AIDS: a qualitative study. Lancet 2001;358:362-367.[ISI][Medline]
  1. Bradley WG, Anderson F, Bromberg M, et al. Current management of ALS: comparison of the ALS CARE database and the AAN practice parameter. Neurology 2001;57:500-504.[Abstract/Full Text]
  1. Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients' perspectives. JAMA 1999;281:163-168.[ISI][Medline]
  1. Krivickas LS, Shockley L, Mitsumoto H. Home care of patients with amyotrophic lateral sclerosis (ALS). J Neurol Sci 1997;152:Suppl 1:S82-S89.[ISI][Medline]


 

 

Edward E. Rylander, M.D.

Diplomat American Board of Family Practice.

Diplomat American Board of Palliative Medicine.